Acorda Therapeutics, Inc. (NASDAQ:ACOR) Short Interest Update

Acorda Therapeutics, Inc. (NASDAQ:ACORGet Free Report) saw a large growth in short interest in the month of February. As of February 29th, there was short interest totalling 11,100 shares, a growth of 7.8% from the February 14th total of 10,300 shares. Based on an average trading volume of 4,700 shares, the days-to-cover ratio is currently 2.4 days. Currently, 0.9% of the shares of the company are short sold.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on Acorda Therapeutics in a research report on Monday, March 11th. They set a “buy” rating for the company.

Read Our Latest Stock Analysis on ACOR

Institutional Trading of Acorda Therapeutics

Several hedge funds have recently modified their holdings of ACOR. Renaissance Technologies LLC lifted its holdings in shares of Acorda Therapeutics by 27.4% in the 2nd quarter. Renaissance Technologies LLC now owns 901,318 shares of the biopharmaceutical company’s stock valued at $420,000 after buying an additional 194,100 shares during the period. Virtu Financial LLC acquired a new stake in shares of Acorda Therapeutics in the 2nd quarter valued at approximately $68,000. Millennium Management LLC increased its stake in Acorda Therapeutics by 661.2% in the 2nd quarter. Millennium Management LLC now owns 311,509 shares of the biopharmaceutical company’s stock valued at $145,000 after purchasing an additional 270,588 shares in the last quarter. Prudential Financial Inc. purchased a new position in Acorda Therapeutics in the 2nd quarter valued at approximately $28,000. Finally, Geode Capital Management LLC increased its stake in Acorda Therapeutics by 44.8% in the 4th quarter. Geode Capital Management LLC now owns 67,669 shares of the biopharmaceutical company’s stock valued at $51,000 after purchasing an additional 20,948 shares in the last quarter.

Acorda Therapeutics Stock Down 4.2 %

ACOR opened at $12.40 on Monday. The company has a debt-to-equity ratio of 3.07, a current ratio of 1.59 and a quick ratio of 1.21. The business has a 50 day simple moving average of $14.90 and a 200-day simple moving average of $13.15. The stock has a market capitalization of $15.38 million, a P/E ratio of -0.72 and a beta of 1.41. Acorda Therapeutics has a 12 month low of $8.98 and a 12 month high of $24.20.

About Acorda Therapeutics

(Get Free Report)

Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen.

Featured Articles

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.